The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions. An evaluation of results ...

Merck (MRK +2.94%) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth. The franchise made up 12% of Merck's sales in the first quarter and ...

Merck said Thursday it closed out the fourth quarter of 2011 with $12.3 billion in sales, a 2% increase from $12 billion in the same period in 2010. While that missed the Street’s consensus for the ...

Januvia (sitagliptin) is a prescription drug for type 2 diabetes that helps lower blood sugar when combined with diet and exercise. Medicare drug plans usually cover this drug. In fact, starting in ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...

Merck has filed applications with the FDA for two additional uses for its diabetes treatment Januvia. Merck is seeking approval for Januvia for the added indications as an adjunct to diet and exercise ...

(The Center Square) – Negotiated lower Medicare costs for 10 popular prescription drugs went into effect Thursday. How much those savings will be passed on to Medicare Part D and applicable Advantage ...

The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically ...

Dear M.A.A.: Sitagliptin (Januvia) is an oral medication for diabetes mellitus. The way it works is complicated: It inhibits a molecule called DPP-4, which causes an increase in another molecule ...

In terms of controlling Type 2 diabetes and potentially obesity, Boston’s Intarcia Therapeutics just released some impressive Phase 3 findings: Its implantable device has been found to be more ...

NEW YORK, Oct 17 (Reuters) - Merck & Co said on Wednesday U.S. regulators have approved use of its Januvia diabetes drug in new combinations with other treatments, but noted reports of serious ...